Oncolytics Reports Promising Pelareorep Data in RAS Cancers
SAN DIEGO, California, USA, June 1, 2026 Oncolytics Biotech has announced encouraging preclinical findings for pelareorep in combination with...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SAN DIEGO, California, USA, June 1, 2026 Oncolytics Biotech has announced encouraging preclinical findings for pelareorep in combination with...
LYON, France — May 28, 2026 Brenus Pharma announced that the U.S. Food and Drug Administration has accepted the...
SAN DIEGO, Calif., May 21, 2026 Cardiff Oncology, Inc. announced that updated data from its ongoing Phase 2 CRDF-004...
INDIANAPOLIS, May 21, 2026 Eli Lilly and Company announced positive topline results from its pivotal Phase 3 TRIUMPH-1 clinical...
PHILADELPHIA and VANCOUVER, British Columbia, May 6, 2026 BriaCell Therapeutics Corp. has received FDA clearance for its Investigational New...
SAN DIEGO, Sept. 2, 2025 – Oncolytics Biotech® Inc. (Nasdaq: ONCY), a clinical-stage immunotherapy company, announced updated clinical safety...
